# Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access

> **NCT04489849** · PHASE4 · UNKNOWN · sponsor: **National Taiwan University Hospital Hsin-Chu Branch** · enrollment: 150 (estimated)

## Conditions studied

- Hemodialysis Access Failure

## Interventions

- **DRUG:** Apixaban 2.5 MG
- **OTHER:** Active Control

## Key facts

- **NCT ID:** NCT04489849
- **Lead sponsor:** National Taiwan University Hospital Hsin-Chu Branch
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-14
- **Primary completion:** 2022-03-14
- **Final completion:** 2022-06-14
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2020-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04489849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04489849, "Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04489849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*